BJMO - volume 10, issue 3, may 2016
P. Dirix MD, PhD, P. Westerlinck MD, G. Buelens MD, P. Huget MD, P. Meijnders MD, PhD
Summary
Skeletal involvement is very common in metastatic prostate cancer and is associated with (symptomatic) skeletal-related events. This article examines the clinical trial data that support the use of available bone-targeted therapies in prostate cancer.
(BELG J MED ONCOL 2016;10(3):97–100)
Read more
BJMO - volume 7, issue 3, july 2013
S. Vandamme , I. Geboers MD, J. Vervliet MD, C. Molderez MD, E. Van den Heuvel MD, J. Gaens MD, P. Meijnders MD, PhD, MD , PhD , W. Tjalma MD, PhD, S. Altintas MD, PhD
Summary
We present the case of a 56-year old patient with primary squamous cell carcinoma of the breast. She underwent a radical mastectomy with adjuvant chemotherapy, consisting of carboplatinum and gemcitabine, and consecutive radiotherapy. Twenty-seven months after her treatment she is still disease-free. Hormonal therapy was initiated for a small tubular carcinoma and is continuing. As yet, there is uncertainty about the correct management of this rare and aggressive type of cancer, but there is growing evidence that adjuvant platinum-based regimens, especially cisplatinum, might be effective in inducing long-term complete remission.
(BELG J MED ONCOL 2013;7(3):89–92)
Read more
Top
